1. Systematic review:
Corinna Dressler, Jo Lambert, Lynda Grine, Paul Galdas, Carle Paul, Miriam Zidane, Alexander Nast
Journal der Deutschen Dermatologischen Gesellschaft (accepted).
Psoriasis is a chronic inflammatory skin condition. Patient education may be one option to improve adherence and coping. The aim of this systematic review is to identify studies evaluating educational interventions for psoriasis patients. The review was conducted following the methods recommended by Cochrane. We searched seven databases, one trial register and three grey literature repositories. Data screening and extraction was done by two t reviewers independently. The risk of bias 2.0, ROBINS-I, NIH-tool were used. Additionally, the APEASE criteria were applied. We evaluat ed 16 studies. Two RCTs evaluated patient-practitioner or patient-nurse one-to-one interventions, one RCT assessed a web-based intervention, three RCTs reported group interventions taking place frequently; one RCT reported one-off group sessions. The remaining RCT compared the health care professionals involved. The risk of bias rating ranged from ‘some concerns’ to ‘high’. Three RCTs found an effect. We included 4 CCTs - one had an effect. One of 4 included before-after-studies warrants further investigation. Despite similarities in delivery mode across the interventions, patients eligible and settings in which interventions were delivered differed. Interventions that included an individual (one-to-one) session appear successful. Two interventions seem suitable for adaptation using APEASE: the topical treatment program (1, 2) and motivational interviewing after climate therapy(3, 4).
The review is being kept updated in form of a living systematic review. We will be searching for new studies every six months starting January 2019.
Table 1: Living Review History
Mota (5) evaluated the effect of several oral education sessions (30 minutes) on awareness of cardiovascular comorbidities amongst psoriasis patients. They report an improvement in knowledge of these comorbidities after the session and after six months. The impact on psoriasis or quality of life was not assessed. Our critical appraisal of the study lead to poor due to suboptimal reporting.
Najafi-Ghezeljeh(6) recruited patients hospitalized with psoriasis to participate in a self-management education intervention comprised of three group session and three telephone calls during which the disease, treatment options, lifestyle and behaviour were discussed. After 3 months, no difference between the intervention and the routine care groups based on final DLQI (mean difference -1.23 [-3.70; 1.24], but a difference was seen based on the mean change in PASI (- 4.21 [-7.81; -0.61]). The risk of bias evaluations lead to moderate for the outcome PASI and serious for the outcome DLQI (ROBINS-I for non-randomized studies). Authors gave no feedback.
Table 2: APEASE(7) evaluation of additional studies
1. Reich K, Mrowietz U, Karakasili E, Zschocke I. Development of an adherence-enhancing intervention in topical treatment termed the topical treatment optimization program (TTOP). Arch Dermatol Res. 2014;306(7):667-76.
2. Reich K, Zschocke I, Bachelez H, de Jong EMGJ, Gisondi P, Puig L, et al. A Topical Treatment Optimisation Programme (TTOP) improves clinical outcome to calcipotriol/betamethasone gel in psoriasis: Results of the 64-week, multinational, randomized, phase IV study in 1790 patients (PSO-TOP). Br J Dermatol. 2017;177(1):197-205.
3. Larsen MH, Krogstad AL, Aas E, Moum T, Wahl AK. A telephone-based motivational interviewing intervention has positive effects on psoriasis severity and self-management: a randomized controlled trial. Br J Dermatol. 2014;171(6):1458-69.
4. Larsen MH, Wahl AK, Krogstad AL, Aas E. Cost-utility Analysis of Supported Self-management with Motivational Interviewing for Patients with Psoriasis. Acta Derm Venereol. 2017;96(5):664-8.
5. Mota F, Selores M, Torres T. Importance of educational sessions on cardiometabolic comorbidities. Awareness among psoriasis patients. Actas Dermo-Sifiliograficas. 2016;107(6):539-41.
6. NAJAFI GHEZELJEH T, SOLTANDEHGHAN K, HOSEINI F. The effect of self-management education on the quality of life and severity of the disease in patients with psoriasis: A clinical trial. Nursing Practice Today. 2018;5(1):243-55.
7. Michie S, Atkins L, West R. The behaviour change wheel : a guide to designing Interventions2014.
8. Bundy C, Kaur-Pinder B, Bucci S, Tarrier N, Griffiths CEM. Managing psychological morbidity in patients with psoriasis using a novel online treatment programme: the e-TIPs study. Br J Dermatol. 2011;165:54.
9. Bundy C, Pinder B, Bucci S, Reeves D, Griffiths CEM, Tarrier N. A novel, web-based, psychological intervention for people with psoriasis: the electronic Targeted Intervention for Psoriasis (eTIPs) study. Br J Dermatol. 2013;169(2):329-36.
10. Bostoen J, Bracke S, De Keyser S, Lambert J. An educational programme for patients with psoriasis and atopic dermatitis: a prospective randomized controlled trial. Br J Dermatol. 2012;167(5):1025-31.
11. Bostoen J, Geusens B, Lambert J, Bracke S, Dekeyser S. An educational program for patients with psoriasis and atopic dermatitis: A prospective randomized, controlled trial. J Am Acad Dermatol. 2012;1):AB84.
12. Rothman AI, Byrne N, Schachter RK, Rosenberg L, Mitchell D. An educational program for psoriatics: an evaluation. Eval Health Prof. 1980;3(2):191-203.
13. Thongkaow S, Kongsin S, Jiamton S, Chunhasewee C, Pratchayapruit W. The Effectiveness of Participation in Self-Help Group on Self-Care Ability and Disease Severity Among Patients with Psoriasis [Master Thesis]. Bangkok: Mahidol University; 2016.
14. Ersser SJ, Cowdell FC, Nicholls PG, Latter SM, Healy E. A pilot randomized controlled trial to examine the feasibility and efficacy of an educational nursing intervention to improve self-management practices in patients with mild-moderate psoriasis. J Eur Acad Dermatol Venereol. 2012;26(6):738-45.
15. Lora V, Gisondi P, Calza A, Zanoni M, Girolomoni G. Efficacy of a single educative intervention in patients with chronic plaque psoriasis. Dermatology. 2009;219(4):316-21.
16. Bremer Schulte M, Cormane RH, van Dijk E, Wuite J. Group therapy of psoriasis. Duo formula group treatment (DFGT) as an example. J Am Acad Dermatol. 1985;12(1 Pt 1):61-6.
17. Fortune DG, Richards HL, Griffiths CE, Main CJ. Targeting cognitive-behaviour therapy to patients’ implicit model of psoriasis: Results from a patient preference controlled trial. Br J Clin Psychol. 2004;43(1):65-82.
18. Fortune DG, Richards HL, Kirby B, Bowcock S, Main CJ, Griffiths CEM. A cognitive-behavioural symptom management programme as an adjunct in psoriasis therapy. Br J Dermatol. 2002;146(3):458-65.
19. Pagliarello C, Calza A, Armani E, Di Pietro C, Tabolli S. Effectiveness of an empowerment-based intervention for psoriasis among patients attending a medical spa. Eur J Dermatol. 2011;21(1):62-6.
20. Renzi C, Di Pietro C, Gisondi P, Chinni LM, Fazio M, Ianni A, et al. Insufficient knowledge among psoriasis patients can represent a barrier to participation in decision-making. Acta Derm Venereol. 2006;86(6):528-34.
21. Burnett CJ, Gordon K, Kundu RV. Psoriasis and cardiometabolic disease: An educational and teaching intervention on cardiometabolic risks. J Am Acad Dermatol. 2015;1):AB101.
22. Burnett CJ, West DP, Rademaker AW, Kundu RV. Psoriasis and Cardiometabolic Disease: A Brief, Focused, Educational Intervention on Cardiometabolic Risks. Journal Of Drugs In Dermatology. 2016;15(10):1176-80.
23. de Korte J, Van Onselen J, Kownacki S, Sprangers MAG, Bos JD. Quality of care in patients with psoriasis: an initial clinical study of an international disease management programme. J Eur Acad Dermatol Venereol. 2005;19(1):35-41.
24. Tucker R, Stewart D. Assessing the impact of community pharmacist led educational advice on knowledge, disease severity and quality of life in patients with mild to moderate psoriasis. Int J Pharm Pract. 2016;24:22.
25. Wahl AK, Moum T, Robinson HS, Langeland E, Larsen MH, Krogstad AL. Psoriasis Patients’ Knowledge about the Disease and Treatments. Dermatol Res Pract. 2013;2013:921737-.
2. Expert survey & Interviews:
[Work in progress]
- 2019/08/12 Focus on...Latin American Clinical Practice Guidelines on the Systemic Treatment of Psoriasis
- 2019/06/03 Focus on...News from our SPIN Columbian members
- 2019/05/21 Focus on...SPIN2019 is now available on your screen!
- 2019/04/18 Focus on...SPIN Congress 2019 in Paris coming soon
- 2019/04/17 Focus on...Do not miss Spin Congress 2019 highlights
News from the web office
- 2017/06/05PIN becomes SPIN - Skin Inflammation & Psoriasis International Network
- 2016/10/29PSO 2016 Congress - Webcasts Available!
- 2016/05/26PIN Survey on Phototherapy
- 2016/02/20PIN Study on Therapeutic Patient Education
- 2016/02/19World Directory of Psoriasis Medical Resources - February 2016 Update
- 2019/04/18 Focus on...SPIN Congress 2019 in Paris coming soon
- 2018/07/16SPIN Symposium at the Spring continental meeting - Tehran, 25-27 April 2018
- 2018/02/222nd National Meeting of the Egyptian Society for Psoriasis
- 2018/02/211st Psoriasis Symposium - Sarajevo 2017
- 2017/06/2815th São Paulo Meeting of Psoriasis and Vitiligo
News from medical groups
- 2018/04/183rd Turkish National Psoriasis Symposium
- 2017/06/21Brazilian Center for Psoriasis Studies joins SPIN!
- 2017/06/21Costa Rica Psoriasis Group - Meet them!
- 2017/02/02Works of the 1st Senegalese Psoriasis Day published!
- 2016/07/29Swiss S1 Guidelines for Systemic treatment of psoriasis vulgaris
News from patients associations
- 2017/02/08France Psoriasis - 2016 World Psoriasis Day
- 2016/05/26Senegal Patients Association joins PIN!
- 2015/08/04Epidermia Greece: a new partner association of PIN
- 2015/08/01Canadian Association of Psoriasis Patients joins PIN!
- 2015/04/09AEPSO Argentina launches digital map to find people with psoriasis in the country
Recent publications on Psoriasis and Atopic Dermatitis
JAK-inhibitors in dermatology: current evidence and future applications.
J Dermatolog Treat. 2019 Nov , 30, (7):648-658.
The Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathway is a ubiquitous intracellular signaling network. Selective JAK-inhibitors have anti-inflammatory properties and have been approved in many countries for the treatment of rheumatoid arthritis (tofacitinib, baricitinib) and myelofibrosis or polycythemia vera (ruxolitinib). The aim of the publication was to summarize and critically analyze the efficacy and safety of JAK-inhibitors in skin diseases, such (...)see on pubmed
Patient preferences for attributes of topical anti-psoriatic medicines.
J Dermatolog Treat. 2019 Nov , 30, (7):659-663.
Patient preferences should be considered when prescribing topical treatments to drive up adherence and improve clinical outcomes. The aim of this work was to identify the most important attributes of topical medicines for psoriasis treatment in the patients' view, and explore the sociodemographic and clinical determinants of these preferences. A questionnaire for the evaluation of the relevancy given to specific attributes of topical medicines used for psoriasis treatment was developed (...)see on pubmed
Salidroside inhibits MAPK, NF-κB, and STAT3 pathways in psoriasis-associated oxidative stress via SIRT1 activation.
Redox Rep.. 2019 Dec , 24, (1):70-74.
To unveil the role of SIRT1 in limiting oxidative stress in psoriasis and to further discuss the therapeutic prospects of salidroside in psoriasis. Literature from 2002 to 2019 was searched with "psoriasis", "oxidative stress", "SIRT1", "salidroside" as the key words. Then, Oxidative stress in psoriasis and the role of SIRT1 were summarized and the potential role of salidroside in the disease was speculated. Oxidative stress might contribute to the pathogenesis of psoriasis. High levels (...)see on pubmed
A case of infective endocarditis associated with atopic dermatitis perioperatively treated with dupilumab.
J Dermatolog Treat. 2019 Nov , 30, (7):674-676.
Several case reports and reviews support a relationship between atopic dermatitis (AD) and infective endocarditis (IE). Here, we present a case of severe AD suspected of causing IE. A 21-year-old man with severe AD was admitted to our hospital due to unidentified fever, syncope, and headache. He was diagnosed with IE with cerebral embolism and mitral regurgitation. Before elective cardiac surgery, he was subcutaneously administered dupilumab for 2 months to control AD. Dupilumab improved (...)see on pubmed
Effect of cinnamamides on atopic dermatitis through regulation of IL-4 in CD4 cells.
J Enzyme Inhib Med Chem. 2019 Dec , 34, (1):613-619.
This study aimed to evaluate the effects of cinnamamides on atopic dermatitis (AD) and the mechanisms underlying these effects. To this end, the actions of two cinnamamides, (E)-3-(4-hydroxyphenyl)-N-phenylethyl acrylamide (NCT) and N-trans-coumaroyltyramine (NCPA), were determined on AD by orally administering them to mice. Oral administration of the cinnamamides ameliorated the increase in epidermal and dermal thickness as well as mast cell infiltration. Cinnamamides suppressed serum (...)see on pubmed
Sublingual immunotherapy of atopic dermatitis in mite-sensitized patients: a multi-centre, randomized, double-blind, placebo-controlled study.
Artif Cells Nanomed Biotechnol. 2019 Dec , 47, (1):3540-3547.
Allergen-specific immunotherapy is widely used for allergic rhinitis and asthma treatment worldwide. This study explored the efficacy and safety of sublingual immunotherapy (SLIT) with the extracts of ( Drops) on house dust mites (HDM)-induced atopic dermatitis (AD). 239 patients with HDM-induced AD were recruited and exposure to a multi-centre, randomized, double-blind, and placebo-controlled clinical trials for 36 weeks, which were randomly divided into placebo and sublingual Drops (...)see on pubmed